Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study-Reference-Cited by-同舟云学术

Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study

Published:2021-03 Issue: Volume:173 Page:108681
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

D'Onofrio Luca,Mignogna Carmen,Carlone Angela,Bellizzi Ermanno,Di Guida Michela,Moretti Chiara,Zampetti Simona,Leto Gaetano,Maddaloni Ernesto,Buzzetti Raffaella

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference19 articles.

1. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43:S111–34. https://doi.org/10.2337/dc20-S010.

2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes;Wiviott;N Engl J Med,2019

3. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial;Gerstein;Lancet (London, England),2019

4. Standard italiani per la cura del diabete mellito;AMD-SID;AMD-SID,2018

5. Diabetes duration and cause-specific mortality in the Verona Diabetes Study;Brun;Diabetes Care,2000

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study;Clinical Therapeutics;2024-07

2. The relationship between HbA1c control pattern and atherosclerosis progression of diabetes: a prospective study of Chinese population;Diabetology & Metabolic Syndrome;2024-06-10

3. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients;Metabolic Syndrome and Related Disorders;2024-04-01

4. Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta‐analysis;ESC Heart Failure;2024-02-28

5. Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study;Diabetes Research and Clinical Practice;2024-01